PHAXIAM Therapeutics SA (DELISTED) (PHXM:DL)
3.10
0.00 (0.00%)
USD |
NASDAQ |
Mar 11, 16:00
PHAXIAM Therapeutics Net Income (Quarterly): -6.195M for Sept. 30, 2023
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2023 | -6.195M |
| December 31, 2022 | 6.069M |
| September 30, 2022 | -5.177M |
| June 30, 2022 | 11.60M |
| March 31, 2022 | -13.37M |
| December 31, 2021 | -13.97M |
| September 30, 2021 | -16.07M |
| June 30, 2021 | -19.29M |
| March 31, 2021 | -14.39M |
| December 31, 2020 | -23.54M |
| Date | Value |
|---|---|
| September 30, 2020 | -21.74M |
| June 30, 2020 | -19.13M |
| March 31, 2020 | -19.41M |
| December 31, 2019 | -21.49M |
| September 30, 2019 | -15.53M |
| June 30, 2019 | -19.80M |
| March 31, 2019 | -13.25M |
| December 31, 2018 | -9.784M |
| September 30, 2018 | -12.42M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-23.54M
Minimum
Dec 2020
11.60M
Maximum
Jun 2022
-13.22M
Average
-15.80M
Median
Net Income (Quarterly) Benchmarks
| DBV Technologies SA | -27.34M |
| Cellectis SA | 5.643M |
| Genfit SA | -- |
| Innate Pharma SA | -- |
| Inventiva SA | -- |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 6.268M |
| EPS Diluted (Quarterly) | -1.020 |
| Enterprise Value | -8.542M |
| Earnings Yield | 96.99% |